Related Experiment Video
Updated: Mar 22, 2026

Isolation and Identification of Extravascular Immune Cells of the Heart
Published on: August 23, 2018
Decrease of circulating myeloid dendritic cells in patients with chronic heart failure
Insights
Circulating myeloid dendritic cells (mDCs) are reduced in chronic heart failure (CHF) patients, with lower levels indicating more severe disease. This finding highlights the role of mDCs in heart failure progression.
Area of Science:
- Immunology
- Cardiology
- Inflammation research
Background:
- Immunity and inflammation are crucial in chronic heart failure (CHF).
- Dendritic cells (DCs) are key immune players, but their role in CHF is unclear.
- This study investigates circulating DCs in compensated CHF patients.
Purpose of the Study:
- To examine circulating myeloid (mDCs) and plasmacytoid (pDCs) dendritic cells in patients with compensated CHF.
- To correlate DC levels with inflammatory cytokines and heart failure severity markers.
Main Methods:
- Flow cytometry was used to analyze mDCs and pDCs in CHF patients (dilated cardiomyopathy [DCM] and ischemic cardiomyopathy [ICM]) and controls.
- Levels of interleukins (IL-6, IL-10) were measured.
- Correlations were assessed between DCs, cytokines, and heart failure parameters (NYHA class, BNP, echocardiography).
Main Results:
- Circulating mDCs were significantly decreased in all CHF patients compared to controls, with lower levels in DCM than ICM.
- No significant changes were found in pDCs.
- Reduced mDCs correlated with poorer left ventricular ejection fraction, larger LV end-diastolic diameter, and higher BNP levels in DCM patients.
- mDCs inversely correlated with IL-6 and IL-10 in all CHF patients.
Conclusions:
- Blood mDCs are decreased in patients with chronic heart failure.
- The reduction in mDCs is associated with the severity of heart failure.
Aims:
Immunity and inflammation processes are known to be of central importance in chronic heart failure (CHF). Dendritic cells (DCs) are key players in adaptive immunity, yet their role in CHF is still unknown. The aim of this study was to investigate the circulating DCs in patients with compensated CHF.
Methods:
Circulating myeloid (m) and plasmacytoid (p) DCs, as well as inflammatory cytokines interleukine (IL) 6 and IL10 were flow cytometrically analysed in peripheral blood of clinically compensated CHF patients with previously diagnosed dilated cardiomyopathy (DCM, n = 69), ischaemic cardiomyopathy (ICM, n = 49), as well as in unaffected controls (n = 51). Correlation analysis was performed between circulating DCs, cytokines and parameters of heart failure severity, such as NYHA class, the marker brain natriuretic peptide (BNP) and echocardiographic parameters of left ventricular function and dilation.
Results:
Circulating mDCs were significantly decreased in all CHF patients, although more pronounced in DCM (0.14%, P < 0.001) than in ICM (0.18%, P = 0.043) compared to controls (0.2%). In contrast, no statistical changes were observed for pDCs. Circulating mDCs correlated with left ventricular ejection fraction (LVEF) and inversely with LV end-diastolic diameter (LVEDd) in all CHF patients. For DCM patients, an inverse correlation of mDCs with BNP was additionally observed. Circulating mDCs correlated inversely with IL6 and IL10 in all CHF patients. With the exception of IL-6 and NYHA class of DCM patients, cytokines did not significantly correlate with heart failure parameters.
Conclusions:
Blood mDCs are decreased in CHF patients. The reduction correlates with the severity of their HF.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure II: Pathophysiology
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
Pathophysiology of Heart Failure
Heart Failure I: Introduction
Heart Failure III: Clinical Manifestations

